journal
MENU ▼
Read by QxMD icon Read
search

Seminars in Oncology

journal
https://www.readbyqxmd.com/read/29248136/uncoupling-tumor-stroma-interactions-in-breast-cancer-patients
#1
EDITORIAL
Carole Sourbier, Len Neckers
No abstract text is available yet for this article.
June 2017: Seminars in Oncology
https://www.readbyqxmd.com/read/29248135/metabolic-symbiosis-in-cancer-and-its-therapeutic-implication
#2
EDITORIAL
Mark R Lipstein, Ipsita Pal, Susan E Bates, Changchun Deng
No abstract text is available yet for this article.
June 2017: Seminars in Oncology
https://www.readbyqxmd.com/read/29248134/pilot-study-demonstrating-metabolic-and-anti-proliferative-effects-of-in-vivo-anti-oxidant-supplementation-with-n-acetylcysteine-in-breast-cancer
#3
Daniel Monti, Federica Sotgia, Diana Whitaker-Menezes, Madalina Tuluc, Ruth Birbe, Adam Berger, Melissa Lazar, Paolo Cotzia, Rossitza Draganova-Tacheva, Zhao Lin, Marina Domingo-Vidal, Andrew Newberg, Michael P Lisanti, Ubaldo Martinez-Outschoorn
BACKGROUND: High oxidative stress as defined by hydroxyl and peroxyl activity is often found in the stroma of human breast cancers. Oxidative stress induces stromal catabolism, which promotes cancer aggressiveness. Stromal cells exposed to oxidative stress release catabolites such as lactate, which are up-taken by cancer cells to support mitochondrial oxidative phosphorylation. The transfer of catabolites between stromal and cancer cells leads to metabolic heterogeneity between these cells and increased cancer cell proliferation and reduced apoptosis in preclinical models...
June 2017: Seminars in Oncology
https://www.readbyqxmd.com/read/29248133/hodgkin-lymphoma-a-complex-metabolic-ecosystem-with-glycolytic-reprogramming-of-the-tumor-microenvironment
#4
Lekha Mikkilineni, Diana Whitaker-Menezes, Marina Domingo-Vidal, John Sprandio, Paola Avena, Paolo Cotzia, Alina Dulau-Florea, Jerald Gong, Guldeep Uppal, Tingting Zhan, Benjamin Leiby, Zhao Lin, Barbara Pro, Federica Sotgia, Michael P Lisanti, Ubaldo Martinez-Outschoorn
BACKGROUND: Twenty percent of patients with classical Hodgkin Lymphoma (cHL) have aggressive disease defined as relapsed or refractory disease to initial therapy. At present we cannot identify these patients pre-treatment. The microenvironment is very important in cHL because non-cancer cells constitute the majority of the cells in these tumors. Non-cancer intra-tumoral cells, such as tumor-associated macrophages (TAMs) have been shown to promote tumor growth in cHL via crosstalk with the cancer cells...
June 2017: Seminars in Oncology
https://www.readbyqxmd.com/read/29248132/mitochondrial-and-glycolytic-metabolic-compartmentalization-in-diffuse-large-b-cell-lymphoma
#5
Mahasweta Gooptu, Diana Whitaker-Menezes, John Sprandio, Marina Domingo-Vidal, Zhao Lin, Guldeep Uppal, Jerald Gong, Roberto Fratamico, Benjamin Leiby, Alina Dulau-Florea, Jaime Caro, Ubaldo Martinez-Outschoorn
Metabolic heterogeneity between neoplastic cells and surrounding stroma has been described in several epithelial malignancies; however, the metabolic phenotypes of neoplastic lymphocytes and neighboring stroma in diffuse large B-cell lymphoma (DLBCL) is unknown. We investigated the metabolic phenotypes of human DLBCL tumors by using immunohistochemical markers of glycolytic and mitochondrial oxidative phosphorylation (OXPHOS) metabolism. The lactate importer MCT4 is a marker of glycolysis, whereas the lactate importer MCT1 and TOMM20 are markers of OXPHOS metabolism...
June 2017: Seminars in Oncology
https://www.readbyqxmd.com/read/29248131/metabolic-coupling-and-the-reverse-warburg-effect-in-cancer-implications-for-novel-biomarker-and-anticancer-agent-development
#6
REVIEW
Lindsay Wilde, Megan Roche, Marina Domingo-Vidal, Katherina Tanson, Nancy Philp, Joseph Curry, Ubaldo Martinez-Outschoorn
Glucose is a key metabolite used by cancer cells to generate ATP, maintain redox state and create biomass. Glucose can be catabolized to lactate in the cytoplasm, which is termed glycolysis, or alternatively can be catabolized to carbon dioxide and water in the mitochondria via oxidative phosphorylation. Metabolic heterogeneity exists in a subset of human tumors, with some cells maintaining a glycolytic phenotype while others predominantly utilize oxidative phosphorylation. Cells within tumors interact metabolically with transfer of catabolites from supporting stromal cells to adjacent cancer cells...
June 2017: Seminars in Oncology
https://www.readbyqxmd.com/read/29248130/guidance-statement-on-brca1-2-tumor-testing-in-ovarian-cancer-patients
#7
REVIEW
Ettore Capoluongo, Gillian Ellison, José Antonio López-Guerrero, Frederique Penault-Llorca, Marjolijn J L Ligtenberg, Susana Banerjee, Christian Singer, Eitan Friedman, Birgid Markiefka, Peter Schirmacher, Reinhard Büttner, Christi J van Asperen, Isabelle Ray-Coquard, Volker Endris, Suzanne Kamel-Reid, Natalie Percival, Jane Bryce, Benno Röthlisberger, Richie Soong, David Gonzalez de Castro
The approval, in 2015, of the first poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi; olaparib, Lynparza) for platinum-sensitive relapsed high-grade ovarian cancer with either germline or somatic BRCA1/2 deleterious mutations is changing the way that BRCA1/2 testing services are offered to patients with ovarian cancer. Ovarian cancer patients are now being referred for BRCA1/2 genetic testing for treatment decisions, in addition to familial risk estimation, and irrespective of a family history of breast or ovarian cancer...
June 2017: Seminars in Oncology
https://www.readbyqxmd.com/read/29248129/the-distribution-of-cancer-cases-in-somalia
#8
Yılmaz Baş, Hussein Abshir Hassan, Cevdet Adıgüzel, Oktay Bulur, İkram Abdikarim Ibrahim, Seçil Soydan
OBJECTIVE: The aim of this study was to investigate the frequency and distribution of cancer cases in a defined time period in Somalia. MATERIALS AND METHODS: A total of 403 cancer cases were diagnosed between January 01, 2016 and March 01, 2017 in the Department of Pathology at the Somalia Mogadishu-Turkey Education and Research Hospital or the Department of Oncology at Uniso Hospital, Somalia University. Data on cancer type, patient age, and gender were obtained from pathology reports and hospital records...
June 2017: Seminars in Oncology
https://www.readbyqxmd.com/read/29248128/management-of-stage-iii-non-small-cell-lung-cancer
#9
REVIEW
Samer Tabchi, Elie Kassouf, Elie El Rassy, Hampig Raphael Kourie, Jocelyne Martin, Marie-Pierre Campeau, Mustapha Tehfe, Normand Blais
Optimal management of patients with locally advanced non-small cell lung cancer remains challenging in the context of this heterogeneous disease. Despite aggressive therapeutic approaches, survival benefits are still unsatisfactory for what might be viewed as a localized malignancy. A combined modality approach offers patients superior outcomes, especially because technological advances and refined surgical procedures now provide better results with fewer complications. Nevertheless, several features of therapy remain controversial and lack formal prospective data...
June 2017: Seminars in Oncology
https://www.readbyqxmd.com/read/28923217/current-challenges-in-the-management-of-breast-cancer-brain-metastases
#10
REVIEW
Ciara C O'Sullivan, Nicole N Davarpanah, Jame Abraham, Susan E Bates
Approximately 50% of patients with advanced human epidermal growth factor 2 (HER2)-positive breast cancer and triple-negative breast cancer (TNBC) ultimately develop breast cancer brain metastases (BCBM), which are associated with significant morbidity and mortality. The advent of HER2-directed therapy resulted in greatly improved survival outcomes, but unfortunately at the price of an increased cumulative incidence of BCBM. We review challenges in the management of BCBM, and potential treatment strategies, including novel agents such as poly-adenosine diphosphate (ADP) ribose polymerase (PARP) inhibitors (olaparib, veliparib), cyclin-dependent kinase 4/6 (CDK4/6) inhibitors (palbociclib, abemaciclib), and taxane derivatives (eg, ANG1005 and TPI-287)...
April 2017: Seminars in Oncology
https://www.readbyqxmd.com/read/28923216/in-reply
#11
LETTER
Michele Boisdron-Celle, Olivier Capitain, Roger Faroux, Christophe Borg, Jean Philippe Metges, Marie Pierre Galais, Mehdi Kaassis, Jaafar Bennouna, Karine Bouhier-Leporrier, Eric Francois, Isabelle Baumgaertner, Véronique Guerin-Meyer, Oana Cojocarasu, Celia Roemer-Becuwe, Claire Stampfli, Ludovic Rosenfeld, Thierry Lecompte, Virginie Berger, Alain Morel, Erick Gamelin
No abstract text is available yet for this article.
April 2017: Seminars in Oncology
https://www.readbyqxmd.com/read/28923215/prevention-of-5-fluorouracil-induced-early-severe-toxicity-by-pre-therapeutic-dihydropyrimidine-dehydrogenase-deficiency-screening-the-multiparametric-approach-is-not-convincing
#12
LETTER
Marie-Christine Etienne-Grimaldi, Chantal Barin Le Guellec, Jean-Christophe Boyer, Etienne Chatelut, Alexandre Evrard, Marie-Anne Loriot, Angelo Paci, Bernard Royer, Fabienne Thomas, Joseph Ciccolini
No abstract text is available yet for this article.
April 2017: Seminars in Oncology
https://www.readbyqxmd.com/read/28923214/commentary-somatostatin-analogs-how-we-choose-and-why
#13
Diane Reidy-Lagunes, Nitya Raj, Leonard Saltz
No abstract text is available yet for this article.
April 2017: Seminars in Oncology
https://www.readbyqxmd.com/read/28923213/long-acting-somatostatin-analogues-in-the-treatment-of-unresectable-metastatic-neuroendocrine-tumors
#14
REVIEW
Thomas Enzler, Tito Fojo
Neuroendocrine tumors (NETs) are a relatively rare and heterogeneous group of neoplasms with an annual incidence of ~35 cases per 100,000 people in the United States. The updated World Health Organization (WHO) classification system of gastroenteropancreatic (GEP)-NETs categorizes these tumors according to site of origin, clinical syndrome, and degree of differentiation. Well-differentiated NETs arising from the gastrointestinal tract or lungs (formerly known as carcinoid tumors) are often indolent and slow-growing...
April 2017: Seminars in Oncology
https://www.readbyqxmd.com/read/28923212/a-molecular-and-preclinical-comparison-of-the-pd-1-targeted-t-cell-checkpoint-inhibitors-nivolumab-and-pembrolizumab
#15
REVIEW
Petros Fessas, Hassal Lee, Shinji Ikemizu, Tobias Janowitz
T-cell checkpoint inhibition has a profound impact on cancer care and the programmed cell death protein 1 (PD-1)-targeted antibodies nivolumab and pembrolizumab have been two of the lead molecules of this therapeutic revolution. Their clinical comparability is a highly relevant topic of discussion, but to a significant degree is a consequence of their molecular properties. Here we provide a molecular, preclinical, and early clinical comparison of the two antibodies, based on the available data and recent literature...
April 2017: Seminars in Oncology
https://www.readbyqxmd.com/read/28923211/nivolumab-and-pembrolizumab-monoclonal-antibodies-against-programmed-cell-death-1-pd-1-that-are-interchangeable
#16
REVIEW
Vinay Prasad, Victoria Kaestner
Nivolumab (Opdivo, Bristol Meyer Squibb, New York, NY) and pembrolizumab (Keytruda, Merck, Kenilworth, NJ) are the first two US Food and Drug Administration (FDA)-approved monoclonal antibodies targeting programmed death-1 (PD-1). Nivolumab and pembrolizumab work by interfering with the interaction between PD-1 and programmed death ligand-1 (PD-L1), whose unimpeded interaction downregulates T cells allowing cancer cells to evade immune surveillance. These drugs have earned a series of FDA approvals for melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell cancer (HNSCC), urothelial cancer, classical Hodgkin lymphoma, and renal cell cancer...
April 2017: Seminars in Oncology
https://www.readbyqxmd.com/read/28923210/angiogenesis-inhibition-in-the-second-line-treatment-of-metastatic-colorectal-cancer-a-definite-conclusion
#17
EDITORIAL
M Ducreux, P Österlund, J P Pignon
No abstract text is available yet for this article.
April 2017: Seminars in Oncology
https://www.readbyqxmd.com/read/28923209/angiogenesis-inhibition-in-the-second-line-treatment-of-metastatic-colorectal-cancer-a-systematic-review-and-pooled-analysis
#18
REVIEW
Ralph Chebib, Loic Verlingue, Nathalie Cozic, Matthieu Faron, Pascal Burtin, Valérie Boige, Antoine Hollebecque, David Malka
The last two decades have seen intensive efforts devoted to the development of compounds that target angiogenesis for the treatment of metastatic colorectal cancer (mCRC). In this review, we describe supporting evidence and ongoing development of angiogenesis inhibitors in the second-line treatment of mCRC, and summarize relevant randomized trials to help therapeutic decision-making in daily practice.
April 2017: Seminars in Oncology
https://www.readbyqxmd.com/read/28923208/cancer-therapies-and-the-problem-of-me-too-many
#19
EDITORIAL
Tito Fojo
No abstract text is available yet for this article.
April 2017: Seminars in Oncology
https://www.readbyqxmd.com/read/28923207/eviction-from-the-sanctuary-development-of-targeted-therapy-against-cell-adhesion-molecules-in-acute-lymphoblastic-leukemia
#20
REVIEW
Sonali P Barwe, Anthony Quagliano, Anilkumar Gopalakrishnapillai
Acute lymphoblastic leukemia (ALL) is a malignant hematological disease afflicting hematopoiesis in the bone marrow. While 80%-90% of patients diagnosed with ALL will achieve complete remission at some point during treatment, ALL is associated with high relapse rate, with a 5-year overall survival rate of 68%. The initial remission failure and the high rate of relapse can be attributed to intrinsic chemoprotective mechanisms that allow persistence of ALL cells despite therapy. These mechanisms are mediated, at least in part, through the engagement of cell adhesion molecules (CAMs) within the bone marrow microenvironment...
April 2017: Seminars in Oncology
journal
journal
24921
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"